This study reports the synthesis of 1,1-bis(2-Carbamoylguanidino)furan-2-ylmethane, characterisation and bioactivities on selected microorganism. The first step involves the coupling of furfural with urea to obtain 1-...This study reports the synthesis of 1,1-bis(2-Carbamoylguanidino)furan-2-ylmethane, characterisation and bioactivities on selected microorganism. The first step involves the coupling of furfural with urea to obtain 1-((2-carbamoylguanidino)(furan-2-ylmethyl)urea, which was subsequently refluxed with more urea in ethanol for 1 hour to afford the product. Both intermediate and product were characterized by GC-MS, IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR. The synthesized compound1,1-bis(2-carbamoylguanidino)furan-2-ylmethane was bioactive on Escherichia coli, Salmomellatyphi and Bacillus subtilis to different extent and is inactive on Staphylococcus aureus. The presences of bioactive moieties and pharmacological activities have proved the potency of furfural derivatives in the development of novel drug in future.展开更多
1-((2-Carbamoylguanidino)(furan-2-ylmethyl)urea was synthesised by coupling purified furfural with urea. The compound was characterized by GC-MS, FTIR, and <sup>1</sup>H-NMR. The pathogens, <i>Escher...1-((2-Carbamoylguanidino)(furan-2-ylmethyl)urea was synthesised by coupling purified furfural with urea. The compound was characterized by GC-MS, FTIR, and <sup>1</sup>H-NMR. The pathogens, <i>Escherichia coli</i>, <i>Salmonella typhi</i>, <i>Staphylococcus aureus</i> and <i>Bacillus subtilis</i> were isolated and screened with different concentrations of 1-((2-carbamoylguanidino)(furan-2-ylmethyl)urea. All the pathogens were susceptible to the synthesized compound except Bacillus subtilis. Due to this broad spectrum of activity, 1-((2-Carbamoylguanidino)(furan-2-ylmethyl))urea) can be use for various medicinal purposes and is therefore encouraged for the development of a novel drug in future.展开更多
文摘This study reports the synthesis of 1,1-bis(2-Carbamoylguanidino)furan-2-ylmethane, characterisation and bioactivities on selected microorganism. The first step involves the coupling of furfural with urea to obtain 1-((2-carbamoylguanidino)(furan-2-ylmethyl)urea, which was subsequently refluxed with more urea in ethanol for 1 hour to afford the product. Both intermediate and product were characterized by GC-MS, IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR. The synthesized compound1,1-bis(2-carbamoylguanidino)furan-2-ylmethane was bioactive on Escherichia coli, Salmomellatyphi and Bacillus subtilis to different extent and is inactive on Staphylococcus aureus. The presences of bioactive moieties and pharmacological activities have proved the potency of furfural derivatives in the development of novel drug in future.
文摘1-((2-Carbamoylguanidino)(furan-2-ylmethyl)urea was synthesised by coupling purified furfural with urea. The compound was characterized by GC-MS, FTIR, and <sup>1</sup>H-NMR. The pathogens, <i>Escherichia coli</i>, <i>Salmonella typhi</i>, <i>Staphylococcus aureus</i> and <i>Bacillus subtilis</i> were isolated and screened with different concentrations of 1-((2-carbamoylguanidino)(furan-2-ylmethyl)urea. All the pathogens were susceptible to the synthesized compound except Bacillus subtilis. Due to this broad spectrum of activity, 1-((2-Carbamoylguanidino)(furan-2-ylmethyl))urea) can be use for various medicinal purposes and is therefore encouraged for the development of a novel drug in future.
